Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Doxecitine→

Doxecitine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
951-77-9
Molecular formula
C9H13N3O4
Molecular weight
227.22 g/mol
Drug class
Deoxycytidine nucleosidepyrimidine nucleoside replacement component of KYGEVVI
Mechanism of action
Supplies deoxycytidine for mitochondrial DNA nucleotide pools. In thymidine kinase 2 deficiency, the combination of deoxycytidine and deoxythymidine is intended to support mitochondrial DNA maintenance and synthesis; the individual nucleosides are administered as a fixed combination, not as separately indicated monotherapies.
Indications / reported uses
  • Component of the fixed combination doxecitine/doxribtimine (KYGEVVI) for treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with symptom onset on or before 12 years of age; not a stand-alone approved indication

Sources: US FDA — KYGEVVI (doxecitine and doxribtimine) approval listing · US DailyMed — KYGEVVI · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Deoxycytidine nucleoside; pyrimidine nucleoside replacement component of KYGEVVI

Mechanism of action

Supplies deoxycytidine for mitochondrial DNA nucleotide pools. In thymidine kinase 2 deficiency, the combination of deoxycytidine and deoxythymidine is intended to support mitochondrial DNA maintenance and synthesis; the individual nucleosides are administered as a fixed combination, not as separately indicated monotherapies.

General use cases

  • Component of the fixed combination doxecitine/doxribtimine (KYGEVVI) for treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with symptom onset on or before 12 years of age; not a stand-alone approved indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Doxecitine Environmental Risk Assessment (ERA) (the Doxecitine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.